Comparing SG&A Expenses: Eli Lilly and Company vs AstraZeneca PLC Trends and Insights

A Decade of SG&A Expenses: Eli Lilly vs AstraZeneca

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, AstraZeneca PLC and Eli Lilly and Company have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, AstraZeneca's SG&A expenses surged by approximately 35%, peaking in 2022. This reflects their aggressive market expansion and strategic investments. In contrast, Eli Lilly maintained a more stable trajectory, with a modest increase of around 5% over the same period, indicating a focus on operational efficiency. Notably, AstraZeneca's expenses were consistently double those of Eli Lilly, highlighting differing business models. As the pharmaceutical landscape continues to shift, these trends offer valuable insights into each company's priorities and market strategies. Understanding these financial dynamics can provide investors and industry analysts with a clearer picture of future growth potential.